Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Patients With Non-Small Cell Lung Carcinoma Who Are Progressing on Erlotinib
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
Over 18
Pharmaceutical / Industry
SNDX-275-0403
NCT00750698
Last Modified:
5/9/2006
 
First Published:
5/1/2001
2.
Phase I Study of MS-275 in Patients With Poor-Risk Hematologic Malignancy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
NCI
JHOC-J0253
MSGCC-0050, NCI-2791, NCT00015925
Last Modified:
10/10/2008
 
First Published:
5/1/2001
3.
Phase I Study of MS-275 in Patients With Advanced Solid Tumors or Lymphomas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
NCI
NCI-01-C-0124
NCI-2792, 2792, NCT00020579
Last Modified:
3/28/2008
 
First Published:
11/22/2004
4.
Phase I Study of MS-275 and Isotretinoin in Patients With Metastatic, Progressive, Refractory, or Unresectable Solid Tumors or Lymphomas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
NCI
JHOC-J0438
6798, NCI-6798, JHOC-04060103, NCT00098891
Last Modified:
4/4/2007
 
First Published:
12/22/2004
5.
Phase I Study of MS-275 and Azacitidine in Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
NCI
JHOC-J0443
NCI-6591, JHOC-04061109, 6591, NCT00101179
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute